Tokyo Tape
Sign in
← Torii Pharmaceutical

Annual report

4551.TEDINET S100T4CW
Period2023-01-01 → 2023-12-31
Filed2024-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 89
MetricValuePeriodScopeSource row
Revenue¥54.6bn2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥48.9bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥47.0bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥41.7bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥43.0bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Operating income¥5.0bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income¥5.5bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income¥5.3bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥5.5bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income¥4.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥5.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.7bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥5.6bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax¥5.7bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income¥4.1bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥3.9bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income¥3.4bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥3.5bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥27.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥133.4bnat 2023-12-31StandaloneAssets
Total assets¥133.7bnat 2022-12-31StandaloneAssets
Total assets¥130.8bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥126.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥139.9bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥13.3bnat 2023-12-31StandaloneLiabilities
Total liabilities¥14.5bnat 2022-12-31StandaloneLiabilities
Net assets / equity¥120.1bnat 2023-12-31StandaloneNet assets
Net assets / equity¥119.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥117.0bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥115.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥113.1bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥5.0bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥9.2bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥34.7bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥45.4bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥58.4bnat 2021-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥61.6bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥58.8bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥3.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥2.4bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥156m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥3.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥42.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥3.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥13.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥7.6bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥2.1bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥146.62023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥140.392022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥120.132021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥124.472020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥974.982019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥124.462020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1202023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002022-01-01 → 2022-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥482021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482019-01-01 → 2019-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,274.45at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,243.08at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,165.38at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,097.55at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,029.3at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio90.0%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.5%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.8%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE3.4%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE3.3%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE2.9%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE3.1%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE27.3%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued28,800,000at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees583at 2023-12-31StandaloneNumber of employees
Employees563at 2022-12-31StandaloneNumber of employees
Employees560at 2021-12-31dStandaloneNumber of employees
Employees568at 2020-12-31dStandaloneNumber of employees
Employees660at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 1
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2023-12-31583 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 949
ItemContextValueUnit
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of voting rights issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember694700
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember28076900
Number of voting rights issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember280769
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember28400
Number of shares issued shares voting rightsCurrentYearInstant28800000
Number of voting rights issued shares voting rightsCurrentYearInstant280769
Number of shares held in own name treasury shares etcCurrentYearInstant_Row1Member694700
Number of shares held in others names treasury shares etcCurrentYearInstant_Row1Member－
Total number of shares held treasury shares etcCurrentYearInstant_Row1Member694700
Shareholding ratio treasury shares etcCurrentYearInstant_Row1Member0.0241
Number of shares held in own name treasury shares etcCurrentYearInstant694700
Number of shares held in others names treasury shares etcCurrentYearInstant－
Total number of shares held treasury shares etcCurrentYearInstant694700
Shareholding ratio treasury shares etcCurrentYearInstant0.0241
Total amount of dividends dividends of surplusFilingDateInstant_Row1Member1405000000JPY
Dividend per share dividends of surplusFilingDateInstant_Row1Member50.00
Total amount of dividends dividends of surplusFilingDateInstant_Row2Member1967000000JPY
Dividend per share dividends of surplusFilingDateInstant_Row2Member70.00
Number of male directors and other officersFilingDateInstant4
Number of female directors and other officersFilingDateInstant1
Ratio of female directors and other officersFilingDateInstant0.200
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000MatsudaGoichiMember18231
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000KondoNobumasaMember4106
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000MatsumuraTakaharuMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000ManabeMihokoMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000FujitaKenichiMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant22337
Audit fees reporting companyPrior1YearDuration38000000JPY
Non audit fees reporting companyPrior1YearDuration－JPY
Audit fees reporting companyCurrentYearDuration39000000JPY
Non audit fees reporting companyCurrentYearDuration－JPY
Audit fees totalPrior1YearDuration38000000JPY
Non audit fees totalPrior1YearDuration－JPY
Audit fees totalCurrentYearDuration39000000JPY
Non audit fees totalCurrentYearDuration－JPY
Audit fees reporting company network firmsPrior1YearDuration－JPY
Non audit fees reporting company network firmsPrior1YearDuration9000000JPY
Audit fees reporting company network firmsCurrentYearDuration－JPY
Non audit fees reporting company network firmsCurrentYearDuration8000000JPY
Audit fees total network firmsPrior1YearDuration－JPY
Non audit fees total network firmsPrior1YearDuration9000000JPY
Audit fees total network firmsCurrentYearDuration－JPY
Non audit fees total network firmsCurrentYearDuration8000000JPY
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember62000000JPY
Base remuneration remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember37000000JPY
Bonus remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember16000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass